natgillin/translations-raw huggingface dataset:
Phosphatidylcholine for use in the method of claim 12, wherein said phosphatidylcholine is administered in a delayed release oral formulation, wherein, preferably, the delayed release is pH-dependent, wherein, preferably, the pH-dependent delayed release formulation comprises a gastric acid resistant substance, wherein the gastric acid resistant substance is preferably selected from the group consisting of film covershields and carrier matrices, or wherein the gastric acid resistant substance comprises preferably acrylpolymers, wherein said acrylpolymer is preferably Eudragit, more preferably Eudragit S100 or Eudragit L30, wherein, preferably, the pH-dependent delayed release oral formulation comprises about 500 mg phosphatidylcholine. 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 12, naznačen time, da se spomenuti fosfatdilkolin primjenjuje kao oralna formulacija s odgođenim otpuštanjem, pri čemu je poželjno da je odgođeno otpuštanje ovisno o pH-vrijednosti, pri čemu je poželjno da formulacija s odgođenim otpuštanjem ovisnim o pH-vrijednosti, sadrži tvar otpornu na želučanu kiselinu, gdje je tvar koja je otporna na želučanu kiselinu poželjno odabrana iz skupine koju čine zaštitni film-omotači i matrice-nosači, ili gdje tvar otporna na želučanu kiselinu sadrži poželjno akrilpolimere, pri čemu spomenuti akrilpolimer je poželjno Eudragit, još bolje Eudragit S100 ili Eudragit L30, dok oralna formulacija koja ima odgođeno otpuštanje ovisno o pH-vrijednosti, poželjno sadrži oko 500 mg fosfatdilkolina,
Phosphatidylcholine for use in the method of claim 12, wherein administration results in a quality of life index score improvement of at least 25%, or wherein administration results in a histology index reduction of at least 25%, or wherein administration results in an endoscopic activity index improvement of at least 50%, or wherein administration results in a clinical activity index improvement of at least 50%, or wherein administration results in cessation of clinically active ulcerative colitis. 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 12, naznačen time, da se rezultati primjene očituju u boljoj kvaliteti života gdje je indeks postignutog poboljšanja barem 25%, ili pri čemu su rezultati primjene takvi da je indeks histološkog smanjenja najmanje 25%, ili pri čemu su rezultati primjene takvi da je indeks poboljšanja endoskopske aktivnosti najmanje 50%, ili pri čemu su rezultati primjene takvi da je indeks poboljšanja kliničke aktivnosti najmanje 50%, ili pri čemu su rezultati primjene takvi da se očituje prestanak kliničke aktivnosti ulcerativnog kolitisa.
identifying an individual having steroid-refractory ulcerative colitis; and administering to said individual a therapeutically effective amount of phosphatidylcholine, thereby ameliorating at least one symptom of said ulcerative colitis. 
identificiranje pojedinca koji ima ulcerativni kolitis otporan na steroide; i davanje tom pojedincu terapeutski djelotvornu količinu fosfatdilkolina, čime se poboljšava barem jedan simptom spomenutog ulcerativnog kolitisa.
A compound represented by the structure of formula V: wherein R7 is a methyl group, and R1', R2', R3', R4' R5', and R6' are the same or different groups selected from dialkylamino, N-piperidine, N-pyrrolidine, N-piperazine, N-piperazine-4-methyl and N-morpholine. 
Spoj predstavljen strukturnom formulom V: [image] u kojoj je R7 metil grupa, a R1', R2', R3', R4' R5', i R6' iste ili različite grupe izabrane od dialkilamino, N-piperidin, N-pirolidin, N-piperazin, N-piperazine-4-metil i N-morfolin.
The compound of claim 1, characterized by formula VI: 
Spoj iz zahtjeva 1, okarakteriziran formulom VI: [image]
The compound of claim 1, characterized by the structure of formula VII: 
Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VII: [image]
The compound of claim 1, characterized by the structure of formula VIII: 
Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VIII: [image]
The compound of claim 1, characterized by the structure of formula IX: 
Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom IX: [image]
The compound of claim 1, characterized by the structure of the formula X: 
Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom X: [image]
The compound of claim 1, characterized by the structure of the formula XI: 
Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom XI: [image]
A pharmaceutical composition comprising the compound of any of claims 1 to 7. 
Farmaceutski sastav koji obuhvaća spojeve iz bilo kojeg od zahtjeva 1 do 7.
The method of claim 1, wherein said compound is represented by the structure of formula VIII: 
Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VIII: [image]
Airbag system for aircrafts intended to protect both cabin crew and passengers, the system comprising: 
Zrakoplov koji sadrži sustav zračnih jastuka namijenjen za zaštitu putnika u putničkoj kabini i posade u kabini za posadu, naznačen time, da sustav zračnih jastuka obuhvaća:
Airbag system for aircrafts intended to protect both its cabin crew and its passengers as claimed in Claim 1 or Claim 2, wherein said inflatable cushions A3-A4-A5 placed at the back of each seat are located inside rectangular-shaped receptacles that can be arranged in three alternative places around the reclining tray and/or the TV monitor for each seat. 
Zrakoplov prema zahtjevu 1, naznačen time, da se spomenuti zračni jastuci (A3, A4, A5) koji su postavljeni na stražnjem dijelu svakog sjedala, nalaze unutar kutije pravokutnog oblika, koja može biti raspoređena u tri alternativna položaja pored naslonskog poslužavnika i/ili pored TV monitora na svakom sjedalu.
The cooker according to claim 1, characterized in that said at least one deformable portion (5) of said gasket (4) is elastically deformable in order to pass from said sealing position to said venting position and vice versa. 
Lonac u skladu s patentnim zahtjevom 1, naznačen time što navedeni najmanje jedan dio koji se može deformirati (5) navedene brtve (4) se može elastično deformirati kako bi se prebacio iz navedenog položaja za brtvljenje u navedeni položaj za ispuštanje vodene pare i obratno.
The compound or the pharmaceutical composition for use according to claim 4 for use in treating allograft transplant rejection in a transplant recipient. 
Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time da je za uporabu kod liječenja odbacivanja presatka kod primatelja presatka.
The compound or the pharmaceutical composition for use according to claim 4 for use in treating a disease and/or disorder of the eye. 
Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time da je za uporabu kod liječenja bolesti i/ili poremećaja oka.
Use of a compound or a pharmaceutical composition according to claim 9 in the manufacture of a medicament for treating allograft transplant rejection in a transplant recipient. 
Uporaba spoja ili farmaceutskog pripravka prema zahtjevu 9 naznačena time da je za proizvodnju medikamenta za liječenje odbacivanja presatka kod primatelja presatka.
An isolated nucleic acid molecule characterized in that it is selected among the following nucleic acids: 
Izolirana molekula nukleinske kiseline, naznačena tim da je odabrana od sljedećih nukleinskih kiselina:
a nucleic acid of at least 18 nucleotides capable of hybridizing under highly stringent conditions with at least one of the 3 CDRs of a heavy chain comprising the nucleic acid sequences SEQ ID Nos. 
nukleinska kiselina od najmanje 18 nukleotida sposobna za hibridizaciju pod vrlo strogim uvjetima s najmanje jednim od 3 CDR teškog lanca koji sadrži sekvenciju nukleinske SEQ ID br.
a nucleic acid of at least 18 nucleotides capable of hybridizing under highly stringent conditions with at least one of the 3 CDRs of a light chain comprising the nucleic acid sequences SEQ ID Nos. 
nukleinska kiselina od najmanje 18 nukleotida sposobna za hibridizaciju pod vrlo strogim uvjetima s najmanje jednim od 3 CDR teškog lanca koji sadrži sekvenciju nukleinske SEQ ID br.
detecting the binding of said antibody with the sample. 
utvrđivanje vezanja rečenog antitijela s uzorkom.
obtaining a signal frame from the demodulated broadcasting signal, wherein the signal frame comprises preamble data symbols and service data symbols; 
dobivanje okvira signala iz demoduliranog digitalnog video emitiranog signala, pri čemu okvir signala obuhvaća simbole početnih nizova i simbole servisnih podataka;
demapping the time-deinterleaved preamble data symbols into preamble data; and decoding the demapped preamble data by LDPC decoding scheme, wherein the preamble data symbols are divided into blocks of equal bandwidth and wherein a bandwidth of the data slice does not exceed a bandwidth of the block. 
demapiranje simbola podataka početnog niza s raspletenim vremenom u podatak početnog niza; i dekodiranje demapiranih podataka početnog niza LDPC shemom dekodiranja, pri čemu su simboli podataka početnog niza podijeljeni u blokove jednake širine pojasa i pri čemu širina pojasa podatkovnog reza ne prelazi širinu pojasa svakog bloka.
means (704-0) for mapping the encoded service data into service data symbols; means (706-0) for building at least one data slice based on the service data symbols, each data slice carrying one or multiple PLPs; 
sredstvo (704-0) za mapiranje kodiranog servisnog podatka u simbole servisnih podataka; sredstvo (706-0) za izgradnju barem jednog podatkovnog reza na temelju simbola servisnih podataka, svaki podatkovni rez nosi pojedine ili višestruke PLP-ove;
means (712) for modulating the built signal frame by an OFDM method; and means for transmitting the modulated signal frame, wherein the preamble data symbols are divided into blocks of equal bandwidth and wherein a bandwidth of the data slice does not exceed a bandwidth of the block. 
sredstvo (712) za moduliranje okvira signala pomoću OFDM metode; i sredstvo za prijenos digitalnog video emitiranog signala uključujući modulirani okvir signala, pri čemu su simboli podataka početnog niza podijeljeni u blokove jednake širine pojasa i pri čemu širina pojasa podatkovnog reza ne prelazi širinu pojasa svakog bloka.
means (r700) for receiving the broadcasting signal; 
sredstvo (r700) za primanje digitalnog video emitiranog signala;
means (r708) for obtaining a signal frame from the demodulated broadcasting signal, wherein the signal frame comprises preamble data symbols and service data symbols; 
sredstvo (r708) za dobivanje okvira signala iz demoduliranog digitalnog video emitiranog signala, pri čemu okvir signala obuhvaća simbole početnih nizova i simbole servisnih podataka;
n is 0, 1, 2, 3, or 4; and denotes a carbon-carbon single or double bond, Y is -C(R"), R' and R" taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring,which is optionally substituted with one or more R2; 
n je 0, 1, 2, 3, ili 4; i [image] predstavlja jednostruku ili dvostruku vezu ugljik-ugljik, Y je -C(R'')-, R' i R" uzeti zajedno s atomima ugljika na koje su vezani tvore arilni ili heteroarilni prsten, koji je po izboru supstituiran s jednom ili više R2;
A pharmaceutical composition comprising said compound or salt of claim 11 in combination with a pharmaceutically acceptable carrier or excipient. 
Farmaceutski pripravak, naznačen time, da sadrži navedeni spoj ili sol prema zahtjevu 11, u kombinaciji s farmaceutski prihvatljivim nosačem ili pomoćnom tvari. prihvatljiv nosač ili pomoćnu tvar.
A pharmaceutical composition for use in treating an inflammatory-related disease associated with cytokine expression levels, comprising at least one compound of Formula (I) or Formula (II) wherein the compound is administered in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression; 
Farmaceutski pripravak za uporabu kod liječenja bolesti povezane s upalom koja je povezana s razinama ekspresije citokina, koji sadrži barem jedan spoj sa Formulom (I) ili Formulom (II) [image] naznačen time da se spoj primjenjuje u količini koja je dovoljna za liječenje bolesti povezane s upalom pomoću inhibicije pro-upalne ekspresije citokina ili pomoću stimulacije protuupalne ekspresije citokina;
Use of at least one compound as defined in claim 1 in the manufacture of a medicament for the treatment of an inflammatory-related disease associated with cytokine expression levels in an animal, wherein the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression; 
Uporaba barem jednog spoja kako je definiran u zahtjevu 1 naznačen time da je za proizvodnju medikamenta za liječenje bolesti povezane s upalom koja je povezana s razinama ekspresije citokina kod životinje, pri čemu je spoj u količini dovoljnoj za liječenje bolesti povezane s upalom pomoću inhibicije pro-upalne ekspresije citokina ili pomoću stimulacije protuupalne ekspresije citokina;
and wherein the inflammatory-related disease is selected from the group consisting of: inflammatory bowel disease; rheumatoid arthritis; and lupus. 
i pri čemu je bolest povezana s upalom odabrana iz skupine koju čine: upalna bolest crijeva; reumatoidni artritis; te lupus.
At least one compound of Formula (I) or Formula (II) as defined in claim 1 for use in the treatment of an inflammatory-related disease associated with cytokine expression levels in an animal, wherein the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression; 
Barem jedan spoj sa Formulom (I) ili Formulom (II) kako je definiran u zahtjevu 1 naznačen time da je za uporabu kod liječenja bolesti povezane s upalom koja je povezana s razinama ekspresije citokina kod životinje, pri čemu je spoj u količini dovoljnoj /.a liječenje bolesti povezane s upalom pomoću inhibicije pro-upalne ekspresije citokina ili pomoću stimulacije protuupalne ekspresije citokina;
The composition for use according to claim 1, or the use according to claim 2, or the compound for use according to claim 3, wherein at least R1 or R2 is a monosaccharide, a disaccharide unsubstituted or substituted with one or more hydroxy moieties or carboxy moieties; a halogen; a hydrocarbyl group, or a functional hydrocarbyl group unsubstituted or substituted with one or more hydroxy moieties, carboxy moieties, nitroxy moieties, monosaccharides, disaccharides, amines, amides, thiols, sulfates, sulfonates, sulfonamides or halogens, wherein the hydrocarbyl has 1 to 8 carbon atoms. 
Pripravak za uporabu prema zahtjevu 1, ili uporaba prema zahtjevu 2, ili spoj za uporabu prema zahtjevu 3, naznačen time da barem R1 ili R2 je monosaharid, disaharid nesupstituiran ili supstituiran sa jednom ili više hidroksi skupina ili karboksi skupina; halogen; hidrokarbil skupina, ili funkcionalna hidrokarbil skupina nesupstituirana ili supstituirana sa jednom ili više hidroksi skupina, karboksi skupina, nitroksi skupina, monosaharidima. disaharidima, aminima, amidima, tiolima, sulfatima, sulfonatima, sulfonamidima ili halogenima, pri čemu hidrokarbil ima 1 do 8 ugljikovih atoma.
and in that said gastro-resistant outer coating comprises: 
te što navedena želučanootporna vanjska obloga sadrži:
An oral pharmaceutical tablet according to claim 1, wherein the pH-dependent release polymer is present in an amount from 15% to 75% by weight of the outer cover layer of the tablet. 
Oralna farmaceutska tableta u skladu s patentnim zahtjevom 1, naznačena time što pH-ovisni polimer za otpuštanje čini. količinski, od 15%) do 75%o, težinski, vanjskog pokrovnog sloja tablete.
An oral pharmaceutical tablet according to claim 1, wherein the outer cover layer of the tablet further comprises a pharmaceutically acceptable excipient selected from an antiadherent, a plasticizer or a colorant. 
Oralna farmaceutska tableta u skladu s patentnim zahtjevom 1, naznačena time što vanjski pokrovni sloj tablete dodatno sadrži farmaceutski prihvatljivu pomoćnu tvar, koja se bira između sredstva protiv prianjanja, plastifikatora ili bojila.
granulating the blended mixture obtained in step a) with water or with an aqueous solution of binder, previously prepared, when the binder is present in step a); 
granuliranja pomiješane smjese dobivene u koraku a) s vodom ili s prethodno pripravljenom vodenom otopinom veziva, kada je vezivo prisutno u koraku a);
drying the granulate obtained in step b); 
sušenja granulata dobivenog u koraku b);
lubricating, if a lubricant is present, the dried granules and compressing it to obtain the core; and 
podmazivanja, ako je prisutno mazivo, osušenih granula, te njihovog komprimiranja kako bi se dobila jezgra; i
Process according to claim 16, wherein in step e) an aqueous dispersion of an alcoholic solution of an antiadherent agent and the pH-dependent polymer and a plastisizer is prepared for coating the core and then obtaining the outer cover layer. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time što se u koraku pripravlja e) vodena disperzija alkoholne otopine sredstva protiv prianjanja, pH-ovisnog polimera i plastifikatora za oblaganje jezgre, a zatim se dobiva vanjski pokrovni sloj.
A method of preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
Postupak dobivanja spoja formule (I): [image], ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
The method of Claim 1 further comprising a preparation of the compound of formula (7), wherein the method comprises treating a compound of formula (6): or a pharmaceutically acceptable salt thereof, under standard Mitsunobu reaction conditions to form the compound of formula (7), or a pharmaceutically acceptable salt thereof. 
Postupak u skladu s patentnim zahtjevom 1, koji se dodatno sastoji u dobivanju spoja formule (7), naznačen time što se postupak sastoji u obradi spoja formule (6): [image], ili njegove farmaceutski prihvatljive soli, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7), ili njegovu farmaceutski prihvatljivu sol.
reacting the intermediate product of a) with a compound of formula (1): or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (4), or a pharmaceutically acceptable salt thereof. 
reakciji međuprodukta iz a) sa spojem formule (1): [image] ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4), ili njegove farmaceutski prihvatljive soli.
The method of Claim 1 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a mixture of enantiomers, under suitable conditions to yield a compound of formula (I- S): or a pharmaceutically acceptable salt thereof, and a compound of formula (I-R): or a pharmaceutically acceptable salt thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u razdvajanju spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-S):
A method of preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, wherein the method comprises: 
Postupak dobivanja spoja formule (I): [image], ili njegove farmaceutski prihvatljive sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, naznačen time što se postupak sastoji u:
treating the compound of formula (6), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, under standard Mitsunobu reaction conditions to form a compound of formula (7): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
[image], ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (6), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7):
treating the compound of formula (7) or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with a base under suitable conditions to form a compound of formula (8): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
[image], ili njegovu farmaceutski prihvatljivu sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (7), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
further hydrogenating the 4-aminophenyl acetic acid obtained in situ in step a) at a temperature between 50-60 °C under 1-4 bar overpressures, then 
daljnjim hidriranjem 4-aminofenil octene kiseline koja je in situ u koraku a) bila dobivena, kod temperature između 50 do 60°C pod nadtlakom od 1 do 4 bara, tada
heating the 4-aminocyclohexyl acetic acid obtained in step b) to reflux for 1-3 hours in hydrochloric ethanol, and if desired after removing the solvent acetonitrile is added to the residue obtained and then distilled off. 
zagrijavanjem 4-aminocikloheksil octene kiseline, koja je dobivena u koraku b), uz povratno hlađenje preko 1 do 3 sata u klorovodik-etanolu i, ako je poželjno, bude nakon odstranjivanja otapala acetonitrila, dobivenom ostatku dodana i tada oddestilirana.
The process according to claim 1, characterized in that in step c) acetonitrile is added to the residue after removing the solvent. 
Postupak prema zahtjevu 1, naznačen time, da u koraku 1) acetonitril, nakon odstranjivanja otapala bude dodan ostatku.
mixing a Leishmania cell with a lysis buffer, 
miješanjem Leishmania stanica s lizirajućim puferom,
centrifuging the obtained mixture to obtain a cytosolic extract, 
centrifugiranjem dobivene smjese za dobivanje citosolskog ekstrakta,
Use according to claim 1, wherein the medicament is for the treatment or prevention of Leishmaniasis in a subject. 
Uporaba u skladu s patentnim zahtjevom 1, pri čemu je lijek za liječenje ili prevenciju lišmanijaze kod subjekta.
Use according to claim 1 or 2, wherein the medicament is a vaccine. 
Uporaba u skladu s patentnim zahtjevom 1 ili 2, pri čemu je lijek cjepivo.
A composition for use as a medicament, wherein said composition comprises a Leishmania Ribosomal Protein Extract, and optionally a Th1- promoting adjuvant, wherein the Leishmania Ribosomal Protein Extract is obtainable by carrying out the following steps using a Leishmania cell causing Leishmaniasis when present in a subject: 
Sastav za uporabu kao lijek, pri čemu navedeni sastav sadrži Leishmania ekstrakt ribosomskog proteina i opcionalno Th-1 promovirajući adjuvans, pri čemu je Leishmania ekstrakt ribosomskog proteina moguće dobiti izvođenjem sljedećih koraka koristeći Leishmania stanice koje uzrokuju lišmanijazu kada je prisutan u subjektu:
A composition for use according to claim 7, consisting of a Leishmania Ribosomal Protein Extract and a Th1 -promoting adjuvant. 
Sastav za uporabu u skladu s patentnim zahtjevom 7, koji sadrži Leishmania ekstrakt ribosomskog proteina i Th-1 promovirajući adjuvans.
A composition for use according to any one of claim 7 to 9, further comprising a pharmaceutically acceptable adjuvant and/or carrier. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 7 do 9, nadalje obuhvaća farmaceutski prihvatljivi adjuvans i/ili nosač.
A composition for use according to any one of claim 7 to 10, wherein the medicament is a vaccine. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 7 do 10, pri čemu je lijek cjepivo.
P is a PEG having a molecular weight in the range from about 17.5 kDa to about 40 kDa; 
P je PEG, čija je molekulska težina u rasponu od otprilike 17,5 kDa do otprilike 40 kDa;